Survival impact of integrative cancer care in advanced metastatic breast cancer
- PMID: 19470134
- DOI: 10.1111/j.1524-4741.2009.00739.x
Survival impact of integrative cancer care in advanced metastatic breast cancer
Abstract
Integrative cancer treatment is of substantial interest to many cancer patients. Research is needed to evaluate the effects of integrative treatment on patient outcomes. We report survival data for a consecutive case series of advanced metastatic breast cancer patients who received a comprehensive clinical program combining conventional treatments with nutrition and supplementation, fitness and mind-spirit instruction at the Block Center for Integrative Cancer Treatment. Treatment outcomes using integrative care for this disease have not previously been documented; survival data will thus contribute to decisions concerning future research directions and design. Ninety consecutive patients with metastatic breast cancer diagnosed during 1984-1997 who received chemotherapy at the integrative cancer center were included. Prognostic factors, treatments and survival from onset of metastases were determined from analysis of scans, labs, pathology and medical records. The log-rank test and Cox proportional hazards analyses were used, and a Kaplan-Meier curve was calculated. All patients had metastatic disease at baseline, 96% were relapsed and 52% had received prior chemotherapy for metastatic disease. Median age at onset of metastasis was 46 years. Median survival was 38 months (95% CI 27,48). Published literature on populations with somewhat more favorable prognostic factors treated in conventional clinics showed median survivals of 20 to 23 months. Through the 1990s, median survival reported in metastatic breast cancer trials or observations generally ranged from 12 to 24 months. Five-year survival was 27% for Center versus 17% for comparison patients. Despite a higher proportion of younger and relapsed patients, survival of metastatic breast cancer patients at the Center was approximately double that of comparison populations and possibly even higher compared to trials published during this period. Explanations for the advantage relative to conventional treatment alone may include the nutritional, nutraceutical, exercise and psychosocial interventions, individually or in combination; self-selection of patients cannot be ruled out. Further research to evaluate the impact of integrative breast cancer treatment on survival is warranted.
Similar articles
-
Brain metastases in breast cancer: prognostic factors and management.Breast Cancer Res Treat. 2008 Oct;111(3):523-30. doi: 10.1007/s10549-007-9806-2. Epub 2007 Nov 8. Breast Cancer Res Treat. 2008. PMID: 17990100
-
Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.Breast J. 2006 Jan-Feb;12(1):37-47. doi: 10.1111/j.1075-122X.2006.00183.x. Breast J. 2006. PMID: 16409585
-
Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.Anticancer Drugs. 2006 Nov;17(10):1193-200. doi: 10.1097/01.cad.0000231485.17063.d3. Anticancer Drugs. 2006. PMID: 17075319
-
Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.Breast Cancer. 2012 Jul;19(3):218-37. doi: 10.1007/s12282-012-0347-0. Epub 2012 Apr 25. Breast Cancer. 2012. PMID: 22532161 Review.
-
Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival.Breast Cancer Res Treat. 2009 May;115(1):7-12. doi: 10.1007/s10549-008-0101-7. Epub 2008 Jun 26. Breast Cancer Res Treat. 2009. PMID: 18581232 Review.
Cited by
-
Design and Synthesis of c-Met and HDAC Dual Inhibitors for the Treatment of Breast Cancer.ACS Med Chem Lett. 2024 Aug 22;15(9):1516-1525. doi: 10.1021/acsmedchemlett.4c00256. eCollection 2024 Sep 12. ACS Med Chem Lett. 2024. PMID: 39291032
-
Benefit of home parenteral nutrition (HPN) and chemotherapy in patients with invasive lobular carcinoma developed peritoneal metastases.Int Cancer Conf J. 2022 Mar 1;11(2):147-151. doi: 10.1007/s13691-022-00539-w. eCollection 2022 Apr. Int Cancer Conf J. 2022. PMID: 35402133 Free PMC article.
-
Designing a broad-spectrum integrative approach for cancer prevention and treatment.Semin Cancer Biol. 2015 Dec;35 Suppl(Suppl):S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Semin Cancer Biol. 2015. PMID: 26590477 Free PMC article. Review.
-
Can we demonstrate that breast cancer "integrative oncology" is effective? A methodology to evaluate the effectiveness of integrative oncology offered in community clinics.Integr Cancer Ther. 2013 Mar;12(2):126-35. doi: 10.1177/1534735412447582. Epub 2012 Jun 27. Integr Cancer Ther. 2013. PMID: 22740079 Free PMC article.
-
Advanced cancer patients in a randomized clinical trial of night-simulating eyeglasses observed to have a normal 24-h circadian rhythm during chemotherapy.SAGE Open Med. 2022 May 23;10:20503121221100137. doi: 10.1177/20503121221100137. eCollection 2022. SAGE Open Med. 2022. PMID: 35646366 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical